Kidney function may change how VC005 drug works

NCT ID NCT07551570

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study looks at how a single dose of VC005 tablets is processed in people with kidney impairment compared to those with normal kidney function. Researchers will measure drug levels in the blood and check safety. The goal is to understand if kidney problems affect how the drug behaves, which can guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VC005 tablets

What this could lead to

If successful, this could help determine safe dosing of VC005 for people with kidney impairment.

What could go wrong

This is a very early Phase 1 study with only 32 people, so results may not apply broadly. It focuses on drug levels, not treatment effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, 233000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••